Abstract:Abstract Background: Chronic kidney disease (CKD) eventually manifests as renal interstitial fibrosis, and loss of peritubular capillaries in the fibrotic area is the main marker of disease progression. Tie2, as the main functional receptor of angiopoietin, is characteristically expressed in vascular endothelial cells. This study aimed to evaluate the effect and mechanism of an agonistic Tie2 monoclonal antibody on folic acid (FA)-induced renal fibrosis (FAN) in mice.Methods: Mice were randomly divided into wild-type mice, FAN model mice, and FAN model mice treated with the agonistic Tie2 antibody. Human umbilical vein endothelial cells with lipopolysaccharide-induced injury were treated with the agonistic Tie2 antibody in vitro.Results: FA-induced renal tubulointerstitial lesions could be prevented with the agonistic Tie2 antibody. The extent of renal fibrosis induced by FA was suppressed by treatment with the agonistic Tie2 antibody. The level of fibroblast-specific protein 1 was reduced in mice that were administered the agonistic Tie2 antibody. Further, the agonistic Tie2 antibody inhibited FA‐induced vascular inflammation by downregulating vascular cell adhesion molecule-1. In addition, peritubular capillary density was upregulated by agonistic Tie2 antibody treatment, as evidenced by an increase in the level of cluster of differentiation 31. These findings were verified by the in vivo results, which showed that the levels of VCAM-1, Bax, and α-smooth muscle actin were downregulated after treatment with the agonistic Tie2 antibody.Conclusions: Based on all these findings, it appears that the agonistic Tie2 antibody attenuated renal interstitial fibrosis in FAN model mice by promoting peritubular capillary regeneration, inhibiting inflammation, and improving peritubular capillary lesions, and therefore, it may have promise for the treatment of CKD.

Targeting Interstitial Myofibroblast-Expressed Integrin αvβ3 Alleviates Renal Fibrosis

Targeting Interstitial Myofibroblast-Expressed Integrin Αvβ3 Alleviates Renal Fibrosis.

Codelivery of Emodin and Diammonium Glycyrrhizinate by Anti-alpha8 Integrin-Conjugated Immunoliposomes for the Treatment of Renal Fibrosis

Targeted Delivery of Celastrol to Renal Interstitial Myofibroblasts Using Fibronectin-Binding Liposomes Attenuates Renal Fibrosis and Reduces Systemic Toxicity.

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Targeted degradation of LRG1 to attenuate renal fibrosis

An Integrin-Based Nanoparticle That Targets Activated Hepatic Stellate Cells and Alleviates Liver Fibrosis.

Extended-Release Of Therapeutic Microrna Via A Host-Guest Supramolecular Hydrogel To Locally Alleviate Renal Interstitial Fibrosis

Treatment of renal interstitial fibrosis with an agonistic Tie2 monoclonal antibody via amelioration of peritubular capillary lesions in a mouse model of nephropathy

A dual αvβ1/αvβ6 integrin inhibitor Bexotegrast (PLN-74809) ameliorates organ injury and fibrogenesis in fibrotic kidney disease

LRG1 Mitigates Renal Interstitial Fibrosis through Alleviating Capillary Rarefaction and Inhibiting Inflammatory and Pro-Fibrotic Cytokines

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

Blocking Interleukin-6 Trans-Signaling Protects Against Renal Fibrosis by Suppressing STAT3 Activation

Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy

Integrin-Targeted Theranostic Nanoparticles for Clinical MRI-Traceable Treatment of Liver Fibrosis

Reduction of Renal Interstitial Fibrosis by Targeting Tie2 in Vascular Endothelial Cells

An injectable micelle-hydrogel hybrid for localized and prolonged drug delivery in the management of renal fibrosis

Blocking antibodies against integrin-α3, -αM, and -αMβ2 de-differentiate myofibroblasts, and improve lung fibrosis and kidney fibrosis

LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation

Ultrasound Assisted a Peroxisome Proliferator-Activated Receptor (ppar)γ Agonist-Loaded Nanoparticle-Microbubble Complex to Attenuate Renal Interstitial Fibrosis

Small Molecules Against the Origin and Activation of Myofibroblast for Renal Interstitial Fibrosis Therapy